Bristol-Myers Squibb Company (BMY)

NYSE: BMY · Real-Time Price · USD
46.20
-1.34 (-2.82%)
At close: Sep 12, 2025, 4:00 PM EDT
46.33
+0.13 (0.28%)
After-hours: Sep 12, 2025, 7:58 PM EDT
-2.82%
Market Cap94.04B
Revenue (ttm)47.70B
Net Income (ttm)5.05B
Shares Out 2.04B
EPS (ttm)2.49
PE Ratio18.58
Forward PE7.23
Dividend$2.48 (5.37%)
Ex-Dividend DateJul 3, 2025
Volume11,894,873
Open47.42
Previous Close47.54
Day's Range46.19 - 47.90
52-Week Range42.96 - 63.33
Beta0.36
AnalystsHold
Price Target57.64 (+24.76%)
Earnings DateOct 30, 2025

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]

Sector Healthcare
Founded 1887
Employees 34,100
Stock Exchange NYSE
Ticker Symbol BMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 15 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $57.64, which is an increase of 24.76% from the latest price.

Price Target
$57.64
(24.76% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500

Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 d...

Other symbols: AMCRARECAGCPBDDOCDOW
2 days ago - Seeking Alpha

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCL...

Other symbols: BNTX
6 days ago - Benzinga

Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Boerner - CEO & Chairman Adam Lenkowsky ...

6 days ago - Seeking Alpha

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the G...

Other symbols: BNTX
6 days ago - Reuters

Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point

Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hod...

6 days ago - Seeking Alpha

Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership

Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy dec...

7 days ago - Seeking Alpha

Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good

Visa has demonstrated why it remains the market leader in the global payment processor market, thanks to its robust, profitable growth cadence.

8 days ago - Seeking Alpha

Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly

Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in...

9 days ago - Seeking Alpha

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: PFEXRAY
10 days ago - Benzinga

Bristol-Myers Squibb: Not As Cheap As It Might Seem

At first glance, Bristol-Myers Squibb appears cheap with a low P/E and strong dividend yield. GAAP earnings are consistently much lower than non-GAAP figures, reflecting costs which may limit cash ava...

11 days ago - Seeking Alpha

7 Big Yields From The Beat-Up Healthcare Sector

Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.

Other symbols: DOCLTCOHIPFESIGASILA
13 days ago - Forbes

8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August Report

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...

Other symbols: BBYCAGEQRKEYKIMKMILYB
14 days ago - Seeking Alpha

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025...

16 days ago - Business Wire

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September...

16 days ago - Business Wire

8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars

I use YCharts' Value Score and Ben Graham Formula to identify large-cap value stocks offering strong intrinsic value and stable dividends. Analyst forecasts suggest top-ten GASV 'Dogs' could deliver 1...

Other symbols: BBVABNSCMCSACNQDHTEEOG
17 days ago - Seeking Alpha

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025.

20 days ago - Business Wire

Final Trades: ServiceNow, Bristol Myers and Live Nation

The Investment Committee give you their top stocks to watch for the second half.

Other symbols: LYVNOW
24 days ago - CNBC Television

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: MDTXRAY
26 days ago - Benzinga

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D...

27 days ago - PRNewsWire

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

Many high-yield S&P 500 stocks are risky, but 19 'safer' dividend dogs have strong free cash flow to support payouts and are worth considering. Analyst forecasts suggest the top ten S&P 500 dividend d...

Other symbols: AMCRAREBXPCAGCPBCVXDOC
4 weeks ago - Seeking Alpha

Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends

The Dividend Harvesting Portfolio rebounded strongly, with profitability up 8.06% and total dividend income now at 19.77% of invested capital. I remain bullish on the S&P 500 reaching 7,000 this year,...

Other symbols: BPMOOSLBSPYI
4 weeks ago - Seeking Alpha

3 SWANs On Sale

Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a li...

Other symbols: ELVREXR
5 weeks ago - Seeking Alpha

3 Dividend Stocks for August 2025

These three dividend payers have an average yield of 4.5%.

Other symbols: AMGNPOR
5 weeks ago - Morningstar

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity

Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused ...

5 weeks ago - Seeking Alpha

Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL).

5 weeks ago - Business Wire